Tocilizumab, Drugs Monitor

(04 May 2021) Tocilizumab- early administration (IL-6 level < 100 pg/ml) may effectively improve the clinical prognosis

May 27, 2021

Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6 https://doi.org/10.3389/fmolb.2021.651662 This study aimed to evaluate the timing and efficacy of TCZ in the treatment of patients with COVID-19. A total of 58 consecutive patients who met… Continue reading "(04 May 2021) Tocilizumab- early administration (IL-6 level < 100 pg/ml) may effectively improve the clinical prognosis"

(03 May 2021) Tocilizumab- improved survival and other clinical outcomes

May 24, 2021

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial https://doi.org/10.1016/S0140-6736(21)00676-0 NCT04381936-Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment… Continue reading "(03 May 2021) Tocilizumab- improved survival and other clinical outcomes"

(09 Apr 2021) Tocilizumab- reduced ICU admissions and mechanical ventilation in early stages

April 29, 2021

Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection https://doi.org/10.37201/req/037.2021 A retrospective study of 171 patients with SARS-CoV-2 infection that did not qualify as requiring transfer to ICU during the first 24h after admission to… Continue reading "(09 Apr 2021) Tocilizumab- reduced ICU admissions and mechanical ventilation in early stages"

(06 Apr 2021) Tocilizumab- early administration was associated with decreased mortality in critically ill patients

April 29, 2021

Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2 https://doi.org/10.1097/CCE.0000000000000395 Eighty-one patients received tocilizumab, and 37 were untreated and served as a control group. Measurements and Main Results: The main… Continue reading "(06 Apr 2021) Tocilizumab- early administration was associated with decreased mortality in critically ill patients"

(02 Apr 2021) Tocilizumab- was found effective in severely or critically ill COVID-19 patients with raised IL-6 levels

April 29, 2021

Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients https://doi.org/10.5005/jp-journals-10071-23747 All patients of the study group had symptomatic presentations with a mean PaO(2)/FiO2 (P/F) ratio of 205.41 before TCZ infusion. All patients had a raised IL-6 level (mean… Continue reading "(02 Apr 2021) Tocilizumab- was found effective in severely or critically ill COVID-19 patients with raised IL-6 levels"

(20 Mar 2021) Tocilizumab-

April 7, 2021

Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series https://doi.org/10.1177/08971900211002353 All patients on admission to intensive care units had severe COVID-19 with 56% requiring mechanical ventilation with a pre-tocilizumab median (IQR) Pao2: Fio2 of 84 (69… Continue reading "(20 Mar 2021) Tocilizumab-"

(10 Mar 2021) Tocilizumab- improved hypoxia without unacceptable side effect profile

April 7, 2021

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial https://doi.org/10.1007/s11684-020-0824-3 ChiCTR2000029765- The patients were randomly assigned in a 1:1 ratio to receive either tocilizumab in addition to standard care or standard care alone. The cure… Continue reading "(10 Mar 2021) Tocilizumab- improved hypoxia without unacceptable side effect profile"

(09 Mar 2021) Tocilizumab- associated with reduced COVID-19 escalation in CRS2 patients

April 7, 2021

Tocilizumab efficacy in COVID-19 patients is associated with respiratory severity-based stages https://www.medrxiv.org/content/10.1101/2021.03.04.21252167v1 The study was conducted from March 3 to April 7 2020 with broad-ranged severity patients; 167 tocilizumab-treated and 327 untreated. CRS1 patients showed no apparent benefit after treatment,… Continue reading "(09 Mar 2021) Tocilizumab- associated with reduced COVID-19 escalation in CRS2 patients"

(28 Feb 2021) Tocilizumab- No detrimental effects for the mother and newborn

March 1, 2021

Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study https://doi.org/10.1111/jcpt.13394 A total of 12 pregnant women were identified to have received tocilizumab during pregnancy in the two hospitals. Median gestational age at admission was 27.7 weeks… Continue reading "(28 Feb 2021) Tocilizumab- No detrimental effects for the mother and newborn"

(26 Feb 2021) Tocilizumab- did not result in significantly better clinical status or lower mortality at 28 days

March 1, 2021

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia https://doi.org/10.1056/NEJMoa2028700 NCT04320615 (COVACTA)- Of the 452 patients who underwent randomization, 438 (294 in the tocilizumab group and 144 in the placebo group) were included in the primary and secondary analyses. The median… Continue reading "(26 Feb 2021) Tocilizumab- did not result in significantly better clinical status or lower mortality at 28 days"

Tag: Tocilizumab